Asset Details
Do you wish to reserve the book?
Bivariate analysis of basal serum anti-Müllerian hormone measurements and human blastocyst development after IVF
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bivariate analysis of basal serum anti-Müllerian hormone measurements and human blastocyst development after IVF
Do you wish to request the book?
Bivariate analysis of basal serum anti-Müllerian hormone measurements and human blastocyst development after IVF
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bivariate analysis of basal serum anti-Müllerian hormone measurements and human blastocyst development after IVF
2011
Overview
Background
To report on relationships among baseline serum anti-Müllerian hormone (AMH) measurements, blastocyst development and other selected embryology parameters observed in non-donor oocyte IVF cycles.
Methods
Pre-treatment AMH was measured in patients undergoing IVF (
n
= 79) and retrospectively correlated to
in vitro
embryo development noted during culture.
Results
Mean (+/- SD) age for study patients in this study group was 36.3 ± 4.0 (range = 28-45) yrs, and mean (+/- SD) terminal serum estradiol during IVF was 5929 +/- 4056 pmol/l. A moderate positive correlation (0.49; 95% CI 0.31 to 0.65) was noted between basal serum AMH and number of MII oocytes retrieved. Similarly, a moderate positive correlation (0.44) was observed between serum AMH and number of early cleavage-stage embryos (95% CI 0.24 to 0.61), suggesting a relationship between serum AMH and embryo development in IVF. Of note, serum AMH levels at baseline were significantly different for patients who did and did not undergo blastocyst transfer (15.6 vs. 10.9 pmol/l;
p
= 0.029).
Conclusions
While serum AMH has found increasing application as a predictor of ovarian reserve for patients prior to IVF, its roles to estimate
in vitro
embryo morphology and potential to advance to blastocyst stage have not been extensively investigated. These data suggest that baseline serum AMH determinations can help forecast blastocyst developmental during IVF. Serum AMH measured before treatment may assist patients, clinicians and embryologists as scheduling of embryo transfer is outlined. Additional studies are needed to confirm these correlations and to better define the role of baseline serum AMH level in the prediction of blastocyst formation.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
